

World Journal of *Clinical Cases*

World J Clin Cases 2023 July 16; 11(20): 4734-4965



MINIREVIEWS

- 4734 Inflammatory myofibroblastic tumor of the distal common bile duct: Literature review with focus on pathological examination
Cordier F, Hoorens A, Ferdinande L, Van Dorpe J, Creytens D
- 4740 Probiotics and autoprobiotics for treatment of *Helicobacter pylori* infection
Baryshnikova NV, Ilina AS, Ermolenko EI, Uspenskiy YP, Suvorov AN
- 4752 Plant-based diet and its effect on coronary artery disease: A narrative review
Mehta P, Tawfeeq S, Padte S, Sunasra R, Desai H, Surani S, Kashyap R

ORIGINAL ARTICLE

Clinical and Translational Research

- 4763 Identification of survival-associated biomarkers based on three datasets by bioinformatics analysis in gastric cancer
Yin LK, Yuan HY, Liu JJ, Xu XL, Wang W, Bai XY, Wang P
- 4788 High expression of autophagy-related gene *EIF4EBP1* could promote tamoxifen resistance and predict poor prognosis in breast cancer
Yang S, Hui TL, Wang HQ, Zhang X, Mi YZ, Cheng M, Gao W, Geng CZ, Li SN
- 4800 Delineation of fatty acid metabolism in gastric cancer: Therapeutic implications
Fu Y, Wang B, Fu P, Zhang L, Bao Y, Gao ZZ
- 4814 Mechanical analysis of the femoral neck dynamic intersection system with different nail angles and clinical applications
Wang Y, Ma JX, Bai HH, Lu B, Sun L, Jin HZ, Ma XL

Retrospective Cohort Study

- 4824 Development and validation of a predictive model for spinal fracture risk in osteoporosis patients
Lin XM, Shi ZC

Retrospective Study

- 4833 Risk prediction model for distinguishing Gram-positive from Gram-negative bacteremia based on age and cytokine levels: A retrospective study
Zhang W, Chen T, Chen HJ, Chen N, Xing ZX, Fu XY
- 4843 Sudden death in the southern region of Saudi Arabia: A retrospective study
Al-Emam AMA, Dajam A, Alrajhi M, Alfaifi W, Al-Shraim M, Helaly AM

- 4852** Diagnostic value of preoperative examination for evaluating margin status in breast cancer

Liu P, Zhao Y, Rong DD, Li KF, Wang YJ, Zhao J, Kang H

Prospective Study

- 4865** Defining the awareness and attitude of the clinicians through pharmacovigilance in Turkey

Aydin OC, Aydin S, Guney HZ

- 4874** Predictive value of the trans-perineal three-dimensional ultrasound measurement of the pubic arch angle for vaginal delivery

Liang ZW, Gao WL

CASE REPORT

- 4883** Microwave ablation of solitary T1N0M0 papillary thyroid carcinoma: A case report

Dionísio T, Lajut L, Sousa F, Violante L, Sousa P

- 4890** Acute spinal subdural haematoma complicating a posterior spinal instrumented fusion for congenital scoliosis: A case report

Michon du Marais G, Tabard-Fougère A, Dayer R

- 4897** Subacute osteomyelitis due to *Staphylococcus caprae* in a teenager: A case report and review of the literature

Vazquez O, De Marco G, Gavira N, Habre C, Bartucz M, Steiger CN, Dayer R, Ceroni D

- 4903** ABCB4 gene mutation-associated cirrhosis with systemic amyloidosis: A case report

Cheng N, Qin YJ, Zhang Q, Li H

- 4912** Metagenomic next-generation sequencing in the diagnosis of neurocysticercosis: A case report

Xu WB, Fu JJ, Yuan XJ, Xian QJ, Zhang LJ, Song PP, You ZQ, Wang CT, Zhao QG, Pang F

- 4920** Drug-coated balloons for treating *de novo* lesions in large coronary vessels: A case report

Zhang ZQ, Qin YR, Yin M, Chen XH, Chen L, Liang WY, Wei XQ

- 4926** Pretreatment with a modified St. Thomas' solution in patients with severe upper limb injuries: Four case reports

Sun ZY, Li LY, Xing JX, Tong LC, Li Y

- 4932** Unexpected diffuse lung lesions in a patient with pulmonary alveolar proteinosis: A case report

Jian L, Zhao QQ

- 4937** Contrast-induced ischemic colitis following coronary angiography: A case report

Qiu H, Li WP

- 4944** Posterior pedicle screw fixation combined with local steroid injections for treating axial eosinophilic granulomas and atlantoaxial dislocation: A case report

Tu CQ, Chen ZD, Yao XT, Jiang YJ, Zhang BF, Lin B

- 4956** Antithrombin III deficiency in a patient with recurrent venous thromboembolism: A case report

Luo JQ, Mao SS, Chen JY, Ke XY, Zhu YF, Huang W, Sun HM, Liu ZJ

- 4961** Laryngospasm as an uncommon presentation in a patient with anti-N-methyl-D-aspartate receptor encephalitis: A case report

Wang L, Su HJ, Song GJ

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Kengo Moriyama, MD, PhD, Associate Professor, Department of Clinical Health Science, Tokai University School of Medicine, Tokai University Hachioji Hospital, Hachioji 1838, Tokyo, Japan. osaru3moving@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJCC as 1.1; IF without journal self cites: 1.1; 5-year IF: 1.3; Journal Citation Indicator: 0.26; Ranking: 133 among 167 journals in medicine, general and internal; and Quartile category: Q4.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Hua-Ge Yin; Production Department Director: Xu Guo; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

PUBLICATION DATE

July 16, 2023

COPYRIGHT

© 2023 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Antithrombin III deficiency in a patient with recurrent venous thromboembolism: A case report

Jia-Qing Luo, Shuai-Shuai Mao, Jin-Yi Chen, Xue-Ying Ke, Yue-Feng Zhu, Wei Huang, Hai-Ming Sun, Zhen-Jie Liu

Specialty type: Medicine, research and experimental

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): C, C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Barik R, India; Oley MH, Indonesia

Received: April 27, 2023

Peer-review started: April 27, 2023

First decision: May 8, 2023

Revised: May 19, 2023

Accepted: June 26, 2023

Article in press: June 26, 2023

Published online: July 16, 2023



Jia-Qing Luo, Hai-Ming Sun, Department of Vascular Surgery, Changxing People's Hospital, Changxing 313100, Zhejiang Province, China

Shuai-Shuai Mao, Department of Endocrinology, Changxing People's Hospital, Changxing 313100, Zhejiang Province, China

Jin-Yi Chen, Zhen-Jie Liu, Department of Vascular Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang Province, China

Xue-Ying Ke, Yue-Feng Zhu, Department of Vascular Surgery, Sir Runrun Shaw Hospital of Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang Province, China

Wei Huang, Department of General Surgery, Changxing People's Hospital, Changxing 313100, Zhejiang Province, China

Corresponding author: Hai-Ming Sun, MD, Chief Physician, Department of Vascular Surgery, Changxing People's Hospital, No. 66 Taihu Middle Road, Changxing 313100, Zhejiang Province, China. sun76543212023@163.com

Abstract

BACKGROUND

Antithrombin III (AT3) deficiency, an autosomal dominant disease, increases the likelihood of an individual developing venous thromboembolism (VTE). Long-term anticoagulation treatment is required for those suffering from AT3 deficiency.

CASE SUMMARY

A man aged 23, who had a history of deep venous thrombosis (DVT), experienced recurrent pain and swelling in his right lower extremity for three days following withdrawal of Rivaroxaban. He was diagnosed with DVT and antithrombin III deficiency as genetic testing revealed a single nucleotide variant in *SERPINC1* (c.667T>C, p.S223P). The patient was advised to accept long-term anticoagulant therapy.

CONCLUSION

Inherited AT3 deficiency due to *SERPINC1* mutations results in recurrent VTE. Patients may benefit from long-term anticoagulant therapy.

Key Words: Antithrombin; Venous thrombosis; SERPINC1; Single nucleotide variant; Anticoagulant therapy; Case report

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Hereditary thrombophilia can be attributed to mutations in genes such as *PROS*, *PROC*, *SERPINC1*, and *F5*. Compared to mutations in other genes, mutations of *SERPINC1* consistently lead to a more pronounced thrombophilia. Patients with this type of mutation are often advised to take warfarin as a therapeutic measure. However, evidence on the efficacy of direct oral anticoagulants is inadequate. Following identification of the *SERPINC1* mutation, our patient was advised to take Rivaroxaban for 5 years to prevent the possibility of thrombus recurrence. This report may supply proof of the efficacy of direct oral anticoagulants in individuals suffering from hereditary thrombophilia.

Citation: Luo JQ, Mao SS, Chen JY, Ke XY, Zhu YF, Huang W, Sun HM, Liu ZJ. Antithrombin III deficiency in a patient with recurrent venous thromboembolism: A case report. *World J Clin Cases* 2023; 11(20): 4956-4960

URL: <https://www.wjgnet.com/2307-8960/full/v11/i20/4956.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v11.i20.4956>

INTRODUCTION

Venous thromboembolism (VTE), consisting of pulmonary embolism (PE) and deep venous thrombosis (DVT), is a significant public health hazard. Approximately 20% of patients have unprovoked VTE. Moreover, 10%~40% of unprovoked VTE patients were diagnosed with inherited thrombophilia[1,2]. Inherited antithrombin III (AT3) deficiency is a particularly concerning form of inherited thrombophilia. AT3 belongs to the serine protease inhibitor superfamily (SERPIN). AT3 is a major inhibitor of plasma serine protease, and it works to inactivate clotting factors like thrombin, as well as factors Xa, IXa, XIa, and XIIa. Different mutations in *SERPINC1* are responsible for Inherited AT3 deficiency, a thrombotic disorder which is inherited in an autosomal dominant fashion[3]. It is estimated that between 0.02%-0.25% of the general population and 2%-5% of those with VTE have inherited AT3 deficiency[4,5]. AT3 deficiency is classified into two phenotypes based on the plasma levels of functional and antigenic AT. Type I is distinguished by a decrease in both functional and antigenic AT, whereas Type II presents with a decrease in functional AT but normal antigenic AT. Type II deficiency is categorized into three groups based on the location of the mutation: Reactive site defects, heparin binding site defects, and pleiotropic defects[4]. We present a case of AT3 deficiency caused by a *SERPINC1* mutation, which was characterized by recurrent DVT.

CASE PRESENTATION

Chief complaints

A 23-year-old man complained of recurrent right lower extremity pain and swelling for three days.

History of present illness

Approximately six months after withdrawing Rivaroxaban, the patient experienced recurrent right lower extremity pain and swelling.

History of past illness

One year ago, the patient came to the hospital complaining of right lower extremity pain for a week. Laboratory examinations before treatment showed the followings: D-dimer level 5.74 µg/mL, hemoglobin level 135 g/L, hematocrit 40.3%, erythrocyte sedimentation rate 6 mm/h, platelet count $241 \times 10^9/L$, fibrinogen level 2.28 g/L, prothrombin time 15 s, active partial thromboplastin time 51.9 s, and the functional AT level AT3 50.5%. Doppler ultrasound revealed venous thrombosis in the right femoral and popliteal veins. After two weeks of initial therapy with low-molecular-weight heparin, the patient left the hospital. He took Rivaroxaban 15 mg twice daily as continuous therapy for a week, which was then changed to Rivaroxaban 10 mg twice daily. The therapy was continued for seven months. The patient then decided to stop anticoagulation therapy.

Personal and family history

There was no record of trauma, malignancy, or other medical issues in his personal history. His parents had no history of thrombosis (Figure 1A).

Physical examination

During physical examination, his vital signs were recorded as follows: body temperature 36.0 °C, blood pressure 110/50




Figure 1 Whole exome sequencing results. A: The patient's parents did not previously have thrombosis and refused to undergo genetic sequencing; B: The mutation was found in *SERPINC1* (c.667T>C); C: The protein change resulted in Serine (S) changed to Proline (P) at position 223 (p.S223P).

mmHg, heart rate 76 bpm, and respiratory rate 18 breaths/min. Furthermore, the right lower limb was swollen.

Laboratory examinations

The patient's functional AT level was 50.5%, indicating AT3 deficiency. Since there were no tests available to measure the antigenic AT level, it is not feasible to identify the subtype of AT3 deficiency in this patient.

Imaging examinations

Computed tomography pulmonary angiography indicated the presence of filling defects in both lobar and partial segmental arteries. Doppler ultrasound of the deep veins in both lower extremities revealed the presence of deep vein thrombosis in the right lower extremity, as well as thrombosis in the middle and lower sections of the right external iliac vein. By computed tomography pulmonary angiography and Doppler ultrasound, the patient was diagnosed with right lower extremity DVT and PE.

FINAL DIAGNOSIS

The patient was diagnosed with DVT, PE and AT3 deficiency.

TREATMENT

During the acute thrombosis, the patient was treated with low-molecular-weight heparin 4100 AxaIU every 12 h. As he was suffering from both DVT and PE, he was recommended to insert an inferior vena filter to prevent worse PE. Upon the discharge, he was advised to receive life-long anticoagulation therapy with Rivaroxaban 20 mg daily.

OUTCOME AND FOLLOW-UP

Over the 5-year follow-up period, no recurrent DVT was observed in this patient.

DISCUSSION

Due to failure to block the coagulation cascade, AT3 deficiency results in a greater risk of recurrent thrombosis[3]. The AT gene, located on chromosome 1 in the q23.1-23.9 region of the genome, is 13.5 kb long and has six introns and seven exons [6]. In 1983, the first variation resulting in AT3 deficiency was reported, and, to our knowledge, more than 200 mutations have been reported to be related to the risk of thrombosis[7]. Furthermore, the mutation profile of the *SERPINC1* gene

includes point mutations, splice site variants, small insertion/deletion mutations, and a few gross rearrangements[4]. The patient in this report had a point mutation. Moreover, the variant was known to result in AT3 deficiency. The AT3 activity in this patient was 50.5%. The decrease in AT3 activity supported the diagnosis.

AT3 deficiency is an autosomal dominant disorder. A heterozygous variant is linked to a heightened probability of venous thrombosis[7]. A heterogeneous variant was found following genome sequencing in this patient. Serine (S) changed to Proline (P) at position 223 (*c.667T>C, p.S223P*) on chromosome 1 (Figure 1B and C). This variant was reported to be a missense change resulting in AT3 deficiency in 1984 and 2000[8,9]. In addition, this variant usually causes type I AT3 deficiency. The initial and recurrent VTE rates are different in type I and type II AT3 deficiency. Mitsuguro *et al*[10] discovered that individuals suffering from type I AT deficiency experienced more VTE occurrences compared to those with type II AT deficiency. Furthermore, Alhenc-Gelas *et al*[11] reported that among a large group of individuals with AT inherited deficiency, type I mutations demonstrated a greater likelihood of experiencing a first VTE, and type II deficiency had a lower risk for PE associated with DVT[11]. In this case, the patient was diagnosed with AT3 activity and a variant in the genotype. After withdrawing Rivaroxaban, he developed PE. We strongly advised the patient to take lifelong anticoagulant therapy.

Rivaroxaban is a selective factor Xa inhibitor. It is widely used in anticoagulation therapy. Many VTE patients prefer Rivaroxaban to warfarin, as it does not require monthly or weekly blood examinations. However, the guidelines did not mention the effects and security of Rivaroxaban in patients with inherited thrombophilia[12,13]. Moreover, few studies have focused on this issue. In our patient, Rivaroxaban seemed to be effective and safe during the six-month treatment. Recurrent VTE occurred quickly after the withdrawal of Rivaroxaban. Thus, Rivaroxaban may be effective in patients with AT3 deficiency. Some case reports have obtained similar outcomes[14-16].

CONCLUSION

When AT3 deficiency is suspected, gene detection is recommended. AT3-deficient patients with *SERPINC1* mutations can be recognized by genetic testing. The discovered mutation in *SERPINC1* (*c.667T>C, p.S223P*) seems to have clinical relevance in AT3 deficiency. Consequently, our patient was advised to modify his lifestyle and start on prolonged prophylactic treatment.

FOOTNOTES

Author contributions: Luo JQ and Mao SS contributed to manuscript writing and editing, and data collection; Chen JY, Ke XY, and Zhu YF contributed to data collection and analysis; Huang W, Sun HM and Liu ZJ contributed to conceptualization and supervision; All authors have read and approved the final manuscript.

Supported by the National Natural Science Foundation of China, No. 81670433 and No. 81970398; the Project of Zhejiang Medical Young Talents (2017); Zhejiang Medical and Health Science and Technology Project, No. 2020RC014; and the Natural Science Foundation of Zhejiang Province, No. LR22H020002.

Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.

Conflict-of-interest statement: Dr. Sun reports grants from the National Natural Science Foundation of China, grants from Zhejiang Medical and Health Science and Technology Project, from the Natural Science Foundation of Zhejiang Province, during the conduct of the study.

CARE Checklist (2016) statement: The authors have read CARE Checklist (2016), and the manuscript was prepared and revised according to CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Jia-Qing Luo 0000-0003-2006-4784; Jin-Yi Chen 0000-0002-8235-6902; Hai-Ming Sun 0009-0001-8184-893X.

S-Editor: Li L

L-Editor: A

P-Editor: Cai YX

REFERENCES

- 1 **Mateo J**, Oliver A, Borrell M, Sala N, Fontcuberta J. Increased risk of venous thrombosis in carriers of natural anticoagulant deficiencies. Results of the family studies of the Spanish Multicenter Study on Thrombophilia (EMET study). *Blood Coagul Fibrinolysis* 1998; **9**: 71-78 [PMID: 9607121 DOI: 10.1097/00001721-199801000-00009]
- 2 **Mateo J**, Oliver A, Borrell M, Sala N, Fontcuberta J. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). *Thromb Haemost* 1997; **77**: 444-451 [PMID: 9065991 DOI: 10.1055/s-0038-1655986]
- 3 **Corral J**, de la Morena-Barrio ME, Vicente V. The genetics of antithrombin. *Thromb Res* 2018; **169**: 23-29 [PMID: 30005274 DOI: 10.1016/j.thromres.2018.07.008]
- 4 **Mulder R**, Croles FN, Mulder AB, Huntington JA, Meijer K, Lukens MV. SERPINC1 gene mutations in antithrombin deficiency. *Br J Haematol* 2017; **178**: 279-285 [PMID: 28317092 DOI: 10.1111/bjh.14658]
- 5 **Wypasek E**, Corral J, Alhenc-Gelas M, Sydor W, Iwaniec T, Celińska-Lowenhoff M, Potaczek DP, Blecharczyk A, Zawilska K, Musiał J, Undas A. Genetic characterization of antithrombin, protein C, and protein S deficiencies in Polish patients. *Pol Arch Intern Med* 2017; **127**: 512-523 [PMID: 28607330 DOI: 10.20452/pamw.4045]
- 6 **Perry DJ**, Carrell RW. Molecular genetics of human antithrombin deficiency. *Hum Mutat* 1996; **7**: 7-22 [PMID: 8664906 DOI: 10.1002/(SICI)1098-1004(1996)7:1<7::AID-HUMU2>3.0.CO;2-B]
- 7 **Navarro-Fernández J**, de la Morena-Barrio ME, Padilla J, Miñano A, Bohdan N, Águila S, Martínez-Martínez I, Sevivas TS, de Cos C, Fernández-Mosteirín N, Llamas P, Asenjo S, Medina P, Souto JC, Overvad K, Kristensen SR, Corral J, Vicente V. Antithrombin Dublin (p.Val30Glu): a relatively common variant with moderate thrombosis risk of causing transient antithrombin deficiency. *Thromb Haemost* 2016; **116**: 146-154 [PMID: 27098529 DOI: 10.1160/TH15-11-0871]
- 8 **Aiach M**, François D, Priollet P, Capron L, Roncato M, Alhenc-Gelas M, Fiessinger JN. An abnormal antithrombin III (AT III) with low heparin affinity: AT III Clichy. *Br J Haematol* 1987; **66**: 515-522 [PMID: 3663508 DOI: 10.1111/j.1365-2141.1987.tb01337.x]
- 9 **Picard V**, Bura A, Emmerich J, Alhenc-Gelas M, Biron C, Houbouyan-Reveillard LL, Molho P, Labatide-Alanore A, Sié P, Toulon P, Verdy E, Aiach M. Molecular bases of antithrombin deficiency in French families: identification of seven novel mutations in the antithrombin gene. *Br J Haematol* 2000; **110**: 731-734 [PMID: 10997988 DOI: 10.1046/j.1365-2141.2000.02245.x]
- 10 **Mitsuguro M**, Sakata T, Okamoto A, Kameda S, Kokubo Y, Tsutsumi Y, Sano M, Miyata T. Usefulness of antithrombin deficiency phenotypes for risk assessment of venous thromboembolism: type I deficiency as a strong risk factor for venous thromboembolism. *Int J Hematol* 2010; **92**: 468-473 [PMID: 20859710 DOI: 10.1007/s12185-010-0687-5]
- 11 **Alhenc-Gelas M**, Plu-Bureau G, Hugon-Rodin J, Picard V, Horellou MH; GFHT study group on Genetic Thrombophilia. Thrombotic risk according to SERPINC1 genotype in a large cohort of subjects with antithrombin inherited deficiency. *Thromb Haemost* 2017; **117**: 1040-1051 [PMID: 28300866 DOI: 10.1160/TH16-08-0635]
- 12 **Kearon C**, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. *Chest* 2016; **149**: 315-352 [PMID: 26867832 DOI: 10.1016/j.chest.2015.11.026]
- 13 **Witt DM**, Nieuwlaar R, Clark NP, Ansell J, Holbrook A, Skov J, Shehab N, Mock J, Myers T, Dentali F, Crowther MA, Agarwal A, Bhatt M, Khatib R, Riva JJ, Zhang Y, Guyatt G. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. *Blood Adv* 2018; **2**: 3257-3291 [PMID: 30482765 DOI: 10.1182/bloodadvances.2018024893]
- 14 **Kawai H**, Matsushita H, Kawada H, Ogawa Y, Ando K. The Successful Prevention of Thromboembolism Using Rivaroxaban in a Patient with Antithrombin Deficiency during the Perioperative Period. *Intern Med* 2017; **56**: 2339-2342 [PMID: 28794370 DOI: 10.2169/internalmedicine.8487-16]
- 15 **Yamaguchi J**, Hara N, Yamaguchi T, Nagata Y, Nozato T, Miyamoto T. Successful treatment of a massive pulmonary embolism using rivaroxaban in a patient with antithrombin III deficiency. *J Cardiol Cases* 2017; **16**: 144-147 [PMID: 30279820 DOI: 10.1016/j.jccase.2017.06.008]
- 16 **Minami K**, Kumagai K, Sugai Y, Nakamura K, Naito S, Oshima S. Efficacy of Oral Factor Xa Inhibitor for Venous Thromboembolism in a Patient with Antithrombin Deficiency. *Intern Med* 2018; **57**: 2025-2028 [PMID: 29526957 DOI: 10.2169/internalmedicine.0483-17]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

